NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
July 10, 2026 — Learn how to get affordable dental implants with smart cost-saving tips from Affordable Dentist Near Me - Crowley. Compare providers, find specials, and explore financing options.
July 9, 2026 — VERAXA Biotech (VRXA) initiates cell line development for lead BiTAC(R) T-cell engager program with ATUM, using Leap-In Transposase technology to advance toward clinical trials. Learn about the potential for safer cancer therapies.
July 9, 2026 — Quantum BioPharma (NASDAQ: QNTM) advances diversified platform with MS drug Lucid-MS and UNBUZZD for alcohol misuse, targeting neurodegenerative and metabolic disorders.
July 9, 2026 — Solana Orthodontics in San Antonio, TX offers braces for kids, teens, and adults with personalized care led by Dr. Sandra Nairooz. Learn about age-specific treatment options.
July 9, 2026 — Learn about cancer treatment resistance mechanisms and how Calidi Biotherapeutics is developing oncolytic virus therapies to overcome it. Stay informed with BioMedWire.
July 9, 2026 — Ocumetics Technology announces positive six-month clinical results, advancing to Group Two surgeries for its next-generation accommodating intraocular lens, with manufacturing underway and strategic partnerships in progress.
July 9, 2026 — LataMed AI Corp. CEO Dr. Kevin Rodan to receive Certificate of Excellence from Ministry of Health for healthcare innovation. Learn about the impact on digital health in Latin America.
July 9, 2026 — Swiss Re CEO Paul Murray warns of a demographic tipping point within ten years as over-65s outnumber 30-59s, urging product innovation in senior health, long-term care, and deferred annuities to redesign retirement and the intergenerational contract.
July 9, 2026 — CCHR Traveling Exhibit in Old Sacramento educates on mental health human rights, informed consent, and coercive treatment. Key speakers address involuntary commitment and patient dignity.
July 9, 2026 — Study reveals hunger amplifies sweet taste appeal regardless of calories; habitual zero-calorie sweetener users show enhanced brain activity in self-control regions, offering new insights for sugar reduction strategies.
July 8, 2026 — VERAXA Biotech (VRXA) initiates cell line development for lead BiTAC T-cell engager program with ATUM, advancing toward clinical studies for safer cancer therapies.
July 8, 2026 — The Hope House maintains a strict 10-client cap per facility, enabling personalized addiction and mental health treatment. Learn how this low-density model enhances privacy and clinical outcomes.
July 8, 2026 — Arizona IOP now accepts Cigna, Aetna, and UMR for outpatient mental health care. Learn how this expansion makes structured IOP treatment more accessible and affordable.
July 8, 2026 — Learn about Arizona IOP's nationally accredited Intensive Outpatient Program, featuring neurofeedback, group therapy, and flexible care. Understand the continuum of care and how IOP bridges residential and outpatient treatment.
July 8, 2026 — New AI tool BRIDGE from Cedars-Sinai matches breast cancer patients to optimal presurgical treatments by analyzing tumor subtypes. Learn how this innovation could improve outcomes.
July 8, 2026 — Scottsdale TMS Therapy confirms insurance coverage for TMS, Spravato, and medication management with Cigna, Aetna, and UMR, reducing costs for treatment-resistant depression, anxiety, and OCD.
July 8, 2026 — Earth Science Tech (ETST) uses a conglomerate business model to integrate telemedicine, pharmacy, real estate, and tech, driving growth and profit margins.
July 8, 2026 — Scottsdale TMS Therapy offers FDA-cleared Transcranial Magnetic Stimulation for treatment-resistant depression. A drug-free, non-invasive alternative with 30-session protocol. Covered by insurance. Visit scottsdaletmstherapy.com.
July 8, 2026 — Scottsdale AZ Detox Center accepts major insurance plans including Cigna, Aetna, and UMR for opioid, alcohol, fentanyl, and benzodiazepine withdrawal. Physician-supervised detox with private accommodations.
July 8, 2026 — NanoViricides receives Outperform rating from Noble Capital Markets with $6 target. CEO discusses NV-387 broad-spectrum antiviral for COVID-19, RSV, influenza, measles, and mpox. FDA Orphan Drug Designation filed.